Antimicrobial Dosing & Renal Clearance Pathway v3.0 Pathogen-Directed Selection, Kinetic GFR & Dialysis Adjustments
📈 Three-Phase Dosing: Loading doses are given at full strength regardless of renal function. Maintenance adjustments begin after 48h. For specialised drugs (Vancomycin, Aminoglycosides, Colistin), the engine generates specific full-course protocols.
1 Patient Characteristics

2 Renal Clearance Status

3 Antimicrobial Selection
Severe Hepatic Impairment (Child-Pugh C)
Renal Replacement Therapy Reference: Select an antimicrobial and dialysis modality to review general clearance characteristics and post-dialysis supplemental dosing recommendations.
💊 Dialysis Clearance Database
📚 The Critical Role of Kinetic GFR in AKI

Traditional equations (Cockcroft-Gault, CKD-EPI) assume a steady state of serum creatinine. In acute critical illness, this assumption is dangerously flawed.

⚠ The Clinical Pitfall
Serum creatinine lags behind actual glomerular filtration by 24 to 48 hours. If a patient’s kidneys completely fail (true GFR = 0), their creatinine will only rise by roughly 1.0 to 1.5 mg/dL per day. A traditional calculator looking at a creatinine of 1.8 mg/dL on Day 1 of AKI might suggest a CrCl of 40 mL/min, leading to massive antibiotic overdosing and subsequent toxicity.
How Kinetic GFR (Jelliffe Formula) Works
  • It evaluates the rate of change in serum creatinine over a specific time interval (e.g., 12 or 24 hours).
  • It incorporates the patient’s estimated Volume of Distribution (Vd) and theoretical creatinine production rate.
  • If creatinine is rising rapidly, the Kinetic GFR will output a severely reduced clearance, reflecting real-time kidney failure long before the absolute creatinine number peaks.
  • Conversely, during recovery, if creatinine is falling, Kinetic GFR will reflect improving clearance, allowing for timely dose escalation to maintain therapeutic efficacy.
Clinical Application

Kinetic GFR is highly recommended by critical care and nephrology guidelines for adjusting doses of antibiotics, particularly narrow-therapeutic-index drugs in the ICU:

  • Aminoglycosides (Amikacin, Gentamicin)
  • Glycopeptides (Vancomycin)
  • Polymyxins (Colistin)
Pharmacokinetic Principles of Antimicrobials
Killing ProfileTarget MetricClinical Strategy
Time-Dependent
(Beta-lactams, Cephalosporins, Carbapenems)
Time > MICFrequent dosing, or extended/continuous infusions to maintain serum levels above the MIC for the longest duration possible.
Concentration-Dependent
(Aminoglycosides, Fluoroquinolones)
Cmax / MICLarge, infrequent doses (e.g., Once-Daily Aminoglycosides) to achieve a massive peak concentration, followed by a drug-free period to minimise toxicity.
Exposure-Dependent
(Vancomycin, Azithromycin)
AUC / MICMaximise the total area under the curve over 24 hours. (For Vancomycin, target AUC/MIC ratio of 400-600).
Abbreviations: CG (Cockcroft-Gault) · CrCl (Creatinine Clearance) · AKI (Acute Kidney Injury) · IBW (Ideal Body Weight) · HD (Haemodialysis) · CRRT (Continuous Renal Replacement Therapy) · MIU (Million International Units) · CMS (Colistimethate Sodium)
⚠ Clinical Disclaimer: Validated for adults (≥ 18 years) only. Provides estimated starting doses based on published guidelines. Must be interpreted in the context of the patient’s specific clinical condition, source of infection, and concurrent organ dysfunction. Always modify therapy based on local antibiograms and definitive cultures.
Algorithm References & Evidence Base
  1. The Sanford Guide to Antimicrobial Therapy (latest edition updates).
  2. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.
  3. Chen S. Retooling the Creatinine Clearance Equation to Estimate Kinetic GFR… J Am Soc Nephrol. 2013;24(5):877-888.
  4. Rybak MJ et al. Therapeutic monitoring of vancomycin for serious MRSA infections… Am J Health Syst Pharm. 2020;77(11):835-864.
  5. Tsuji BT et al. International Consensus Guidelines for the Optimal Use of the Polymyxins. Pharmacotherapy. 2019;39(1):10-39.
MEDiscuss Clinical Decision Support Suite

Access all evidence-based algorithms, prognostic matrices, and pharmacotherapeutic pathways.

View All Clinical Modules